Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain.
For more details on financing and valuation for Annexon Biosciences, register or login.
By registering, you agree to Forge’s Terms of Use. Already registered? Log in
ANNX
2.99 as of 5/31/23
To read this article and more news on Annexon Biosciences, register or login.
